Diabetes Care:基线HbA1c和β-细胞功能可预测T2DM

2013-10-12 佚名 丁香园

糖耐量受损(IGT)个体发生2型糖尿病(T2DM)的风险较高。为了检查可预测T2DM发生的基线特征,来自德克萨斯糖尿病研究所的Defronzo博士等进行了一项研究。结果表明,基线时仅HbA1c和β-细胞功能能够预测糖尿病的发生。研究结果发表于2013年9月23日的美国《糖尿病治疗》(Diabetes Care)杂志上。【原文下载】 研究对象为228名ACT NOW研究中经安慰剂治疗的高危IGT受

糖耐量受损(IGT)个体发生2型糖尿病(T2DM)的风险较高。为了检查可预测T2DM发生的基线特征,来自德克萨斯糖尿病研究所的Defronzo博士等进行了一项研究。结果表明,基线时仅HbA1c和β-细胞功能能够预测糖尿病的发生。研究结果发表于2013年9月23日的美国《糖尿病治疗》(Diabetes Care)杂志上。【原文下载】

研究对象为228名ACT NOW研究中经安慰剂治疗的高危IGT受试者,这些受试者均经过基线人体测量、基线及随访期2.4年后口服葡萄糖耐量试验(OGTT)。

结果显示,在单变量分析中,228名IGT受试者中有45名(19.7%)发生糖尿病。经年龄、性别和试验中心校正后,升高的空腹血糖、2h血糖、OGTT中G0-120、HbA1c、脂肪细胞胰岛素抵抗指数、空腹血浆胰岛素对数值和0-120分钟胰岛素对数值与糖尿病风险增高有关,此外,糖尿病家族史和代谢综合症也与糖尿病风险增高有关。基线时,OGTT中胰岛素分泌(ln [I0-120/G0-120])增高与糖尿病风险降低有。β-细胞功能(胰岛素分泌/胰岛素抵抗指数或处置指数)升高是与糖尿病风险降低最密切相关的变量(OR为0.11,P<0.0001)。

研究表明,在逐步多变量回归分析中,仅HbA1c和β-细胞功能能够预测糖尿病的发生。

原文检索

Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, Gastaldelli A; for the ACT NOW Study.Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk.Diabetes Care. 2013 Sep 23. 【原文下载】

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636746, encodeId=15c71636e467e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 28 04:35:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015886, encodeId=149420158860b, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 17 16:35:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901146, encodeId=cc29190114654, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Mar 11 07:35:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759351, encodeId=dbfe1e59351f6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jun 11 14:35:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586773, encodeId=2a871586e732e, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636746, encodeId=15c71636e467e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 28 04:35:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015886, encodeId=149420158860b, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 17 16:35:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901146, encodeId=cc29190114654, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Mar 11 07:35:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759351, encodeId=dbfe1e59351f6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jun 11 14:35:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586773, encodeId=2a871586e732e, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
    2014-07-17 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636746, encodeId=15c71636e467e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 28 04:35:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015886, encodeId=149420158860b, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 17 16:35:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901146, encodeId=cc29190114654, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Mar 11 07:35:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759351, encodeId=dbfe1e59351f6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jun 11 14:35:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586773, encodeId=2a871586e732e, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636746, encodeId=15c71636e467e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 28 04:35:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015886, encodeId=149420158860b, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 17 16:35:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901146, encodeId=cc29190114654, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Mar 11 07:35:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759351, encodeId=dbfe1e59351f6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jun 11 14:35:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586773, encodeId=2a871586e732e, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636746, encodeId=15c71636e467e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 28 04:35:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015886, encodeId=149420158860b, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 17 16:35:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901146, encodeId=cc29190114654, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Mar 11 07:35:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759351, encodeId=dbfe1e59351f6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jun 11 14:35:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586773, encodeId=2a871586e732e, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]

相关资讯

ADA 2013:减重手术在T2DM治疗中的地位

近年来,减重手术已成为糖尿病治疗领域的研究热点之一。 第73届美国糖尿病学会(ADA) 年会的ADA/欧洲糖尿病研究学会(EASD)联合专场针对这一话题,分别从减重手术的临床实践、减重手术对神经内分泌学及微生物学的影响等方面进行了热 烈的讨论。此外,本届年会首次以“专家见面会”(Meet The Expert)的形式来促进参会者与专家面对面的交流,其中最有学术影响力、

Diabetes Care:甘油和脂肪酸或可预测T2DM

为了研究空腹血清甘油和脂肪酸(FAs)作为高血糖恶化预测因子与2型糖尿病发生的相关性。来自东芬兰大学医学院的Laakso博士等人进行了一项研究,研究发现,空腹血清甘油、FFAs、单不饱和FAs、n-7和n-9 FAs水平是高血糖和2型糖尿病发生风险增高的标志物,而血清n-6 FAs水平升高与高血糖和2型糖尿病风险减少相关。研究结果在线发表于2013年9月11日的美国《糖尿病

NEJM:阿格列汀能安全用于T2DM患者合并心血管高危风险(EXAMINE研究)

   对于T2DM患者合并心血管高危风险(15-90天内有急性心梗和不稳定性心绞痛住院患者),加用阿格列汀(alogliptin)或安慰剂治疗,发现alogliptin并不增加主要大血管事件,对于糖尿病合并心血管高危风险患者是安全的。这是EXAMINE研究的核心结果。结果将于ESC荷兰阿姆斯特丹当地时间9月2日上午11:18公布;NEJM 新英格兰杂志将同步于ESC期间发表。 原始出处

ADA 2013:纪立农认为ORBIT研究示中国T2DM患者胰岛素治疗不及时

    2013年第73届美国糖尿病协会科学年会(ADA2013)于6月21日~25日在美国芝加哥隆重举办,在ADA2013年会上,北京大学第一医院纪立农教授有5篇中国研究入选壁报讨论(2篇 General Poster Sessions)和会议摘要(3篇 Published Only)。其中一篇会议摘要题目为“中国ORBIT研究的设计及9760位患者的基线资料:在真

ADA 2013:达格列净(Dapagliflozin )单药治疗未曾用药的T2DM安全有效

    2013年第73届美国糖尿病协会科学年会(ADA2013)于6月21日~25日在美国芝加哥隆重举办。在ADA2013年会上,北京大学第一医院纪立农教授有5篇中国研究入选壁报讨论(2篇 General Poster Sessions)和会议摘要(3篇 Published  Only)。其中一篇壁报为“单纯饮食或运动控制不佳的亚洲2型糖尿病患者使用达格列

Diabetes Care:ω-3多不饱和脂肪酸或可降低T2DM风险

鱼类或ω-3多不饱和脂肪酸(PUFA)与2型糖尿病的关系尚不明确。鱼类中的污染物,如水银,甚至都可能会改变其中的作用。为了研究芬兰中老年男性血清中ω-3 PUFAs:二十碳五烯酸(EPA),二十二碳五烯醇(DPA)、二十二碳六烯酸(DHA)、α-亚麻酸(ALA)及发汞与2型糖尿病发生风险的相关性,来自芬兰库奥皮奥东芬兰大学公共卫生和临床营养研究院的Virtanen等进行了一项研究,血清长链ω-3